Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament |
Trials |
|
|
clinical deterioration | clinical improvement | deaths | viral clearance |
Immunostimulants drugs | 38 | 0.56 [0.36; 0.89], 7 RCTs, I2=0% demonstrated low degree of certainty | 1.06 [0.78; 1.45], 5 RCTs, I2=45% inconclusive result | 1.05 [0.97; 1.13], 19 RCTs, I2=0% inconclusive result | 6.72 [2.07; 21.82], 2 RCTs, I2=0% moderate degree of certainty | |
Immunosuppressants drugs | 33 | 0.79 [0.58; 1.08], 5 RCTs, I2=17% inconclusive result | 1.28 [1.11; 1.48], 10 RCTs, I2=37% demonstrated low degree of certainty | 0.86 [0.77; 0.97], 15 RCTs, I2=3% demonstrated safety concern inconclusive result | - | |
corticosteroids | 20 | 0.70 [0.40; 1.23], 5 RCTs, I2=73% inconclusive result | 3.34 [0.36; 30.90], 2 RCTs, I2=86% inconclusive result | 0.93 [0.83; 1.03], 12 RCTs, I2=37% demonstrated inconclusive result | - | |
anti-inflammatory therapies | 5 | OBS 0.43 [0.02; 8.34], 2 studies, I2=88% inconclusive result | OBS 12.75 [1.61; 100.79], 1 study, I2=0% unassessable degree of certainty | OBS 0.55 [0.29; 1.03], 2 studies, I2=15% inconclusive result | - | |
acalabrutinib | 2 | - | - | - | - | |
leflunomide | 1 | 1.00 [0.02; 52.54], 1 RCT, I2=0% inconclusive result | - | 1.00 [0.02; 52.54], 1 RCT, I2=0% inconclusive result | - | |
A EFFACER anticorps | 0 | - | - | - | - | |
Apilimod | 0 | - | - | - | - | |
imatinib | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - | |